An agency of the European Union
Frequent searches:
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 14-20 March 2026 and includes updates on respiratory virus epidemiology in the EU/EEA, chikungunya, dengue, avian influenza, invasive meningococcal disease, aedes aegypti detection in Luxembourg, and measles.
Communicable disease threats report, 21 – 27 March 2026, Week 13
English (3.67 MB - PDF)
This interactive dashboard provides a weekly integrated epidemiological summary for influenza, RSV and SARS-CoV-2.
This page includes the selection committees that have been appointed for the ongoing selection procedures.
Most respiratory viruses are declining across the EU/EEA: Influenza circulation and hospitalisations are decreasing. SARS CoV 2 activity is low. RSV activity remains elevated, with children under five years the most affected.
The European Centre for Disease Prevention and Control (ECDC) hosted a joint workshop, bringing together ECDC Management Board members and ECDC National Focal Points for Preparedness and Response to take stock of progress with the Public Health Emergency Preparedness Assessments* (PHEPA) that are being conducted by ECDC across the European Union/European Economic Area (EU/EEA) countries.
The Management Board approves and monitors the implementation of ECDC’s work programme and budget, it adopts its annual report and accounts - all in all, it acts as the governing body of the Centre.
ECDC regularly assesses new evidence on variants detected through epidemic intelligence, rules-based genomic variant screening or other scientific sources.
A human case of avian influenza A(H9N2) infection in a returning traveller from a non-European country where the virus has previously been identified in birds, has been reported in the Lombardy region of Italy. This is the first human case of avian influenza A(H9N2) reported in the EU/EEA.
This overview presents key recommendations based on updates submitted by EU/EEA countries in 2023 regarding prevention, preparedness, response planning, and implementation at national level.
ECDC’s new practical guide offers detailed instructions for designing and conducting in-action and after-action reviews to strengthen Europe’s public health emergency preparedness and response.
In-action reviews (IARs) and after-action reviews (AARs) – referred to collectively in this guide as ‘action reviews’ – provide a structured way to capture and act on the lessons learned during an ongoing or past public health emergency response.
Guide for designing and conducting in-action and after-action reviews
English (5.86 MB - PDF)
Workshop under the EU-funded Health Resilience in the Eastern Partnership project aim to help countries turn lessons from the COVID-19 pandemic into practical actions for stronger, more resilient public health laboratories.
Reporting protocol for submitting data on antimicrobial consumption to ECDC, through the European Antimicrobial Consumption Surveillance Network (ESAC-Net).
Tuberculosis remains a significant public health challenge in Europe, despite often being considered a disease of the past.
Tuberculosis (TB) is a major cause of morbidity and mortality in Europe. High-quality laboratory diagnosis of TB is the basis for both individual patient treatment and surveillance.
Handbook on tuberculosis laboratory diagnostic methods in the European Union - updated 2026
English (5.31 MB - PDF)
World Tuberculosis Day, marked each year on 24 March, is an occasion to raise awareness and advocate for efforts to eliminate TB.
Between 2025 and 2030, ECDC predicts that 9 350 deaths could be preevented if we met our global targets
There is a widening gap between the observed notifcation rates of TB and our targets.
Tuberculosis treatment outcomes in the European Region, 2024
Infographic: Pulmonary TB cases in the European Region, 2024
Multidrug-resistant (MDR) tuberculosis in the EU/EEA, 2024
TB incidence per 100000 population and deaths notification in the EU/EEA, 2024
Tuberculosis treatment outcomes in the EU/EEA, 2024
TB incidence per 100000 population in the EU/EEA, 2024
Treating TB needs integrated care, with prevention, screening and reliable diagnosis. ECDC constantly monitors progress in treating TB across the EU/EEA to achieve these goals.